Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim PK/PD and Safety Study in Healthy Adults
NCT05366283Phase 1Completed
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of sargramostim in pulmonary alveolar proteinosis (PAP), Alzheimer's disease (AD) and neutropenia. Primary endpoints: Maximum Concentration at 24 hours, Time to Maximum Concentration at 24 hours and 4 more. Started Apr 2022; status: completed.
02
Drugs
sargramostim
03
Conditions
pulmonary alveolar proteinosis (PAP)Alzheimer's disease (AD)neutropenia
Beyond the preview
Go deeper on NCT05366283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366283.